Agios Pharmaceuticals Inc

Most Recent

  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.

    By Daniel Collins
  • uploads///Omeros
    Company & Industry Overviews

    Why Omeros Stock Rose Last Week

    On April 2, 2018, Omeros (OMER) stock opened at $11.12. It grew ~22% over the week to close at $13.58 on April 6.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View Agios Pharmaceuticals and Peers in March 2018

    Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

    By Kenneth Smith
  • uploads///AGIO
    Company & Industry Overviews

    An Insight into Agios Pharmaceuticals’ Product Pipeline

    Agios Pharmaceuticals’ (AGIO) product pipeline includes ivosidenib, which is targeted for mutated IDH1 and AG-881.

    By Kenneth Smith
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Athenex and Its Peers in March

    Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating.

    By Kenneth Smith
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Collaboration
    Company & Industry Overviews

    Behind Jazz’s Strategic Collaboration with ImmunoGen

    In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17

    In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Jazz Pharmaceuticals Expects for Vyxeos

    If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017

    In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

    By Margaret Patrick
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Celgene in August 2017

    Of the 27 analysts covering Celgene (CELG) in August 2017, 12 analysts recommended a “strong buy,” and ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Oncology Pipeline
    Company & Industry Overviews

    An Overview of Celgene’s Hematology and Oncology Pipeline

    In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Announces Data from Phase 2 Study of PK Deficiency

    Agios Pharmaceuticals was one of the top performers among the small-cap segment within the iShares Nasdaq Biotechnology ETF (IBB) on June 13, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Remained Stable as the Markets Rallied on Higher Oil Prices

    On June 8, the biotech and healthcare sectors had a mixed day and remained sluggish. The SPDR S&P Biotech ETF (XBI) gained 0.1% for the day. XBI has fallen by 16.4% on a year-to-date basis.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%

    Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Small-Caps Are Topping the IBB Portfolio

    Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data

    On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Falls as Energy Sector Negatively Influences the Market

    The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie, Lead Performer of the Pharmaceutical Subgroup

    AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    IBB Was among the Best Biotechnology ETFs for the Week

    Biotechnology ETFs outperformed the broader market and posted some positive gains for the week. The iShares NASDAQ Biotechnology ETF gave a return of 2.9%.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Agios Outperformed: Rose 24.8% and Helped IBB Gain 3.2%

    Agios Pharmaceuticals (AGIO) rose by a staggering 24.8% on October 27, 2015. It was the top performer in IBB’s portfolio.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.